Effect of Antidepressant Switching vs Augmentation on Remission among Patients with Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial -

Effect of Antidepressant Switching vs Augmentation on Remission among Patients with Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Information type: Randomised controlled trials
Source: Journal of the American Medical Association
Specialities: Mental health and illness
Summary
In a 12-week follow-up of a RCT of 1522 patients with major depressive disorder (85% men) unresponsive to previous antidepressant treatment, 29% achieved remission after augmenting their antidepressant with aripiprazole vs 22% who switched to bupropion.
UKMi comment
A related editorial discusses these study findings in relation to STAR*D, concluding that since the population studied was predominantly male with 44% diagnosed with post-traumatic stress disorder, augmentation with atypical antipsychotic agents could have a potential role in this setting.
Related links: Editorial